Bergen, Norway, 05 February 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the fourth quarter and full year 2018 on Tuesday, 12 February 2019. A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Hotel ContinentalStortingsgaten 24/260117 Oslo The presentation will webcast live and the link will be available … Read more
ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development Phase I dose escalation and expansion trial will evaluate ADCT-601 in 75 cancer patients ADCT-601 is BerGenBio’s third clinical candidate targeting AXL Bergen, Norway, January 21 2019 – BerGenBio ASA (OSE:BGBIO), announces that the first patient has been dosed … Read more
BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers Bergen, Norway, January 9 2019 – BerGenBio ASA (OSE:BGBIO),a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat … Read more
Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting a corporate overview at the Biotech Showcase 2019 in San Francisco today at 10:00 am PST. The presentation will webcast live and the … Read more
Phase II monotherapy study of bemcentinib in high-risk MDS & AML Will enrol up to 43 patients at leading MDS centres across Europe Investigator sponsored trial led by Prof. Uwe Platzbecker Bergen, Norway, Jan 4th 2019 – BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of … Read more
Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for Companion Diagnostic Significant milestones expected over next 12 months Bergen, Norway, 12 Dec 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class … Read more
43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) Phase II trial continues in combination with chemotherapeutics in first line AML Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congress Bergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE: … Read more
Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of clinical development in multiple aggressive cancers Bergen, Norway, 22nd November 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as … Read more
Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, … Read more
Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients Median progression-free-survival (mPFS) of 5.9 months in AXL positive vs 3.3 months in AXL negative patients (~80% improvement) Predominantly PD-L1 negative or weak-positive patient population Bergen, Norway, 6 November … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.